Chimerix (NASDAQ: CMRX) announced completion of enrollment of the targeted 200 patients in the Phase 3 AdVise trial evaluating brincidofovir ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE